Netherlands Diabetes Devices Market Outlook 2026–2034: Digital Health Adoption Fuels Strong Growth

The Netherlands diabetes devices market is poised for significant expansion over the next decade, driven by rising diabetes prevalence, strong reimbursement policies, and rapid adoption of digital health technologies. According to Renub Research, the market is projected to grow from US$ 392.4 million in 2025 to US$ 737.3 million by 2034, registering a robust compound annual growth rate (CAGR) of 7.27% between 2026 and 2034.

This growth reflects the Netherlands’ progressive healthcare model, which prioritizes early diagnosis, preventive care, and continuous disease management. With approximately 1.2 million people living with diabetes in the country — nearly 10% of whom have type 1 diabetes — the demand for advanced monitoring and insulin delivery solutions continues to rise steadily.

Download Free Sample Report:https://www.renub.com/request-sample-page.php?gturl=netherlands-diabetes-market-p.php

Understanding Diabetes Devices: A Core Component of Modern Disease Management

Diabetes devices refer to medical technologies used to monitor blood glucose levels and assist in insulin administration. These devices play a critical role in preventing long-term complications such as cardiovascular disease, neuropathy, kidney failure, and vision impairment.

The main categories include:

• Self-Monitoring of Blood Glucose (SMBG) devices

• Continuous Glucose Monitoring (CGM) systems

• Insulin pumps

• Insulin pens (disposable and reusable)

• Digital health applications integrated with glucose monitoring systems

Modern diabetes devices increasingly incorporate wireless communication, smartphone connectivity, and real-time alerts. These features allow data sharing between patients and healthcare providers, enabling more personalized treatment adjustments.

In the Netherlands, diabetes devices have become an established pillar of long-term disease management, supported by structured clinical pathways and strong patient education initiatives.

Key Growth Drivers in the Netherlands Diabetes Devices Market

1. Strong Emphasis on Preventive and Self-Managed Care

The Dutch healthcare system emphasizes preventive medicine and patient empowerment. Diabetes management in the Netherlands encourages individuals to self-monitor glucose levels regularly and actively adjust lifestyle and treatment regimens.

Devices such as SMBG meters, CGMs, and insulin pens support this model by enabling patients to track glucose trends independently. This proactive approach increases device penetration and repeat purchases, particularly for consumables like sensors and test strips.

Preventive care strategies reduce hospital admissions and long-term complications, reinforcing the role of diabetes devices in outpatient and homecare settings.

2. High Acceptance of Digital Health Technologies

The Netherlands ranks among Europe’s most digitally advanced healthcare ecosystems. Citizens and healthcare professionals alike are comfortable adopting innovative medical technologies.

This digital maturity has accelerated the uptake of smart insulin pens, app-integrated CGMs, and remote monitoring platforms. Real-time data access improves patient engagement and allows clinicians to optimize therapy based on continuous glucose insights.

In February 2024, Dexcom Inc launched the Dexcom ONE+ real-time continuous glucose monitoring system across Europe. The customizable device, wearable on multiple body sites, reflects the growing demand for flexible and user-friendly CGM solutions in markets like the Netherlands.

As telemedicine and data-driven healthcare continue to evolve, demand for connected diabetes management systems is expected to remain strong.

3. Robust Reimbursement Framework and Healthcare Access

The Netherlands offers widespread access to advanced diabetes devices through supportive reimbursement policies. Insulin-dependent patients, in particular, benefit from insurance coverage for CGMs and insulin pumps, reducing financial barriers to adoption.

This reimbursement stability encourages early device adoption and long-term adherence. For instance, in 2023, Roche introduced the Accu-Chek Guide system to the Dutch market, offering enhanced usability compared to previous models. Such product launches, supported by reimbursement systems, accelerate market penetration.

With a well-structured primary care network and coordinated diabetes management programs, device utilization continues to expand across homecare and clinical environments.

Market Challenges Impacting Growth

Cost Pressures in High-Tech Device Adoption

While adoption rates are strong, advanced diabetes devices such as CGMs and insulin pumps involve recurring expenses for sensors, infusion sets, and maintenance. Healthcare authorities continuously assess cost-effectiveness to ensure sustainable reimbursement.

Budgetary constraints could slow the pace of adoption for premium technologies, even in a well-funded healthcare system like the Netherlands.

Usability and Patient Adaptation Barriers

Despite high awareness levels, not all patients feel comfortable using advanced digital technologies. Older individuals may encounter challenges with device setup, data interpretation, or mobile app integration.

Continuous wear requirements and sensor replacement can also affect compliance. Addressing these concerns through education and training remains essential for sustained growth.

Segment Analysis: Device-Level Insights

Netherlands SMBG Device Market

The self-monitoring of blood glucose (SMBG) market in the Netherlands is mature and stable. Glucometers, test strips, and lancets remain fundamental tools for both type 1 and type 2 diabetes patients.

Although growth is slower compared to CGMs, replacement demand and ongoing use among newly diagnosed and elderly patients ensure steady revenues. SMBG devices remain a cost-effective and accessible solution, particularly for patients not requiring continuous monitoring.

Netherlands CGM Device Market

The CGM segment is the fastest-growing category in the Dutch diabetes devices market. Continuous monitoring enables real-time glucose tracking, trend analysis, and hypoglycemia alerts, significantly improving glycemic control.

CGMs are widely used among type 1 diabetes patients and insulin-dependent type 2 patients. Smartphone integration and remote data-sharing capabilities strengthen their appeal.

Major industry players such as Abbott Laboratories and Medtronic continue to expand their CGM portfolios, intensifying competition and innovation in the market.

Netherlands Insulin Pump Industry

Insulin pumps deliver continuous subcutaneous insulin infusion, offering superior glycemic control compared to multiple daily injections. The Dutch market supports pump adoption through structured training and reimbursement programs.

Although pumps require patient education and come with higher upfront costs, they provide flexibility and improved quality of life, particularly for type 1 diabetes patients.

Technological integration with CGM systems has further enhanced pump functionality, contributing to market expansion.

Netherlands Insulin Pen Device Market

Insulin pens remain widely accepted due to their portability, dosing accuracy, and ease of use. Both disposable and reusable variants are available, catering to diverse patient needs.

Smart insulin pens with tracking and connectivity features are gradually gaining popularity, reflecting the broader digital transformation in diabetes care.

Companies like Eli Lilly and Terumo Corporation continue to innovate in this segment.

Distribution and End-User Landscape

Hospitals and Diagnostic Centers

Hospitals and diagnostic centers play a critical role in diagnosis, treatment planning, and professional CGM usage. These facilities rely on advanced glucose monitoring systems to evaluate glycemic patterns and optimize therapy.

The Netherlands’ preventive healthcare orientation ensures that diagnostic centers remain central to early detection and ongoing management.

Homecare Segment

Homecare is rapidly expanding as patients increasingly manage diabetes independently. Portable devices, digital connectivity, and structured support programs enable effective at-home monitoring and insulin administration.

The shift toward home-based management aligns with broader healthcare efficiency goals.

Retail Pharmacy Channel

Retail pharmacies serve as a key distribution channel for glucose meters, test strips, insulin pens, and CGM sensors. Their accessibility and advisory support make them a critical interface between patients and diabetes technologies.

As diabetes prevalence rises, pharmacies continue to play a vital role in ensuring consistent device availability.

City-Level Market Dynamics

Major Dutch cities such as Amsterdam, Rotterdam, The Hague, Utrecht, and Eindhoven exhibit higher device penetration due to advanced healthcare infrastructure and specialist clinics. Urban populations typically show stronger adoption of digital health technologies compared to smaller cities.

However, nationwide insurance coverage ensures relatively uniform access across regions.

Competitive Landscape and Key Companies

The Netherlands diabetes devices market is competitive and innovation-driven. Leading companies include:

• Dexcom Inc

• Medtronic

• Roche

• Abbott Laboratories

• Eli Lilly

• Terumo Corporation

• BD

These companies focus on product innovation, digital integration, strategic partnerships, and expanded reimbursement collaborations to strengthen their market positions.

Market Segmentation Overview

By Type

• Self-Monitoring Devices (Test Strips, Lancets, Blood Glucose Meters)

• Continuous Glucose Monitoring Devices (Sensors, Transmitters, Receivers)

• Insulin Pumps (Patch Pumps, Tethered Pumps, Consumables)

• Insulin Pens (Disposable and Reusable)

By End User (Volume)

• Hospitals

• Diagnostic Centers

• Homecare

By Key Cities
Amsterdam, Rotterdam, The Hague, Utrecht, Eindhoven, Groningen, Tilburg, Almere, Breda, Nijmegen

Final Thoughts

The Netherlands diabetes devices market stands at the intersection of digital innovation, preventive healthcare, and strong reimbursement support. With Renub Research forecasting growth from US$ 392.4 million in 2025 to US$ 737.3 million by 2034 at a CAGR of 7.27%, the market trajectory reflects sustained confidence in technology-driven diabetes management.

High digital literacy, structured care pathways, and government-backed reimbursement policies create an enabling environment for advanced glucose monitoring and insulin delivery devices. While cost pressures and usability challenges remain considerations, continuous innovation and patient education are likely to address these barriers.

As diabetes prevalence continues to rise, the Netherlands is expected to remain one of Europe’s most progressive and technologically integrated diabetes device markets, offering strong opportunities for manufacturers, healthcare providers, and digital health innovators alike.